Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 3
1951 1
1954 2
1955 1
1956 1
1957 1
1958 2
1959 3
1960 11
1961 20
1962 49
1963 52
1964 61
1965 53
1966 21
1967 26
1968 21
1969 28
1970 23
1971 22
1972 21
1973 20
1974 27
1975 23
1976 29
1977 27
1978 41
1979 45
1980 72
1981 163
1982 482
1983 654
1984 864
1985 1149
1986 1097
1987 1239
1988 1355
1989 1501
1990 1472
1991 1595
1992 1636
1993 1675
1994 1709
1995 2016
1996 2393
1997 2308
1998 2330
1999 2130
2000 2225
2001 2126
2002 1953
2003 2067
2004 1964
2005 1926
2006 1999
2007 1939
2008 1894
2009 1911
2010 1920
2011 1872
2012 1861
2013 1925
2014 1748
2015 1702
2016 1505
2017 1445
2018 1328
2019 1292
2020 1394
2021 1284
2022 1126
2023 1058
2024 283

Text availability

Article attribute

Article type

Publication date

Search Results

66,364 results

Results by year

Filters applied: . Clear all
Page 1
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA. 2002 Dec 18;288(23):2981-97. doi: 10.1001/jama.288.23.2981. JAMA. 2002. PMID: 12479763 Clinical Trial.
Five-year systolic blood pressures were significantly higher in the amlodipine (0.8 mm Hg, P =.03) and lisinopril (2 mm Hg, P<.001) groups compared with chlorthalidone, and 5-year diastolic blood pressure was significantly lower with amlodipine (0.8 …
Five-year systolic blood pressures were significantly higher in the amlodipine (0.8 mm Hg, P =.03) and lisinopril (2 mm Hg, P& …
Heterogeneity in Blood Pressure Response to 4 Antihypertensive Drugs: A Randomized Clinical Trial.
Sundström J, Lind L, Nowrouzi S, Hagström E, Held C, Lytsy P, Neal B, Marttala K, Östlund O. Sundström J, et al. JAMA. 2023 Apr 11;329(14):1160-1169. doi: 10.1001/jama.2023.3322. JAMA. 2023. PMID: 37039792 Free PMC article. Clinical Trial.
INTERVENTIONS: Each participant was scheduled for treatment in random order with 4 different classes of blood pressure-lowering drugs (lisinopril [angiotensin-converting enzyme inhibitor], candesartan [angiotensin-receptor blocker], hydrochlorothiazide [thiazide], a …
INTERVENTIONS: Each participant was scheduled for treatment in random order with 4 different classes of blood pressure-lowering drugs (li
Amlodipine: an overview of its pharmacodynamic and pharmacokinetic properties.
van Zwieten PA. van Zwieten PA. Clin Cardiol. 1994 Sep;17(9 Suppl 3):III3-6. Clin Cardiol. 1994. PMID: 9156957 Free article. Review.
Amlodipine, a third-generation dihydropyridine calcium antagonist, has a mode of action and pharmacodynamic profile which are comparable to those of conventional compounds in this series, such as nifedipine. ...It possesses, therefore, a strong affinity for cell mem
Amlodipine, a third-generation dihydropyridine calcium antagonist, has a mode of action and pharmacodynamic profile which are
Management of amlodipine-induced ankle oedema.
Skovbjerg BK, Helgestad OK, Oxlund CS, Christensen B, Henriksen JN. Skovbjerg BK, et al. Ugeskr Laeger. 2023 Apr 17;185(16):V07220460. Ugeskr Laeger. 2023. PMID: 37114573 Free article. Review. Danish.
Pedal oedema is a well-known adverse effect of amlodipine, but significantly less frequent if only half of the maximum recommended dosage is used. ...To cause as few side effects as possible, options for managing are prioritised in this review: Reduce dosage, switch to ler …
Pedal oedema is a well-known adverse effect of amlodipine, but significantly less frequent if only half of the maximum recommended do …
Amlodipine in the Era of New Generation Calcium Channel Blockers.
Tiwaskar M, Langote A, Kashyap R, Toppo A. Tiwaskar M, et al. J Assoc Physicians India. 2018 Mar;66(3):64-9. J Assoc Physicians India. 2018. PMID: 30341872 Review.
Amlodipine is a longer acting dihydropyridine calcium channel blocker, effective for 24 hours BP control and cause no BP variability. ...Novel type of calcium channel blockers have been developed which have additional properties of
Amlodipine is a longer acting dihydropyridine calcium channel blocker, effective for 24 hours BP control and cau
THE NITROSAMINE CONTAMINATION IN BETA BLOCKERS (BISOPROLOL/METOPROLOL), ACE INHIBITORS (LISINOPRIL/PERINDOPRIL), THIAZIDES DIURETICS (HCT), CALCIUM CHANNEL BLOCKERS (AMLODIPINE/FELODIPINE), SARTANS (CANDESARTAN) AND HE SUBSEQUENT SKIN CANCER DEVELOPMENT AND PROGRESSION: APOCALYPSE NOW.
Tchernev G. Tchernev G. Georgian Med News. 2023 Apr;(337):138-145. Georgian Med News. 2023. PMID: 37354687
Of further concern is the evidence of contamination of newer classes of medications by nitrosamines- namely: beta blockers, calcium antagonists and selective serotonin reuptake inhibitors (SSRIs). ...This article presents, for the first time in the world literature, …
Of further concern is the evidence of contamination of newer classes of medications by nitrosamines- namely: beta blockers, calciu
Analytical and Bioanalytical Techniques for the Quantification of the Calcium Channel Blocker - Amlodipine: A Critical Review.
Kokilambigai KS, Kavitha J, Seetharaman R, Lakshmi KS, Sai Susmitha A. Kokilambigai KS, et al. Crit Rev Anal Chem. 2021;51(8):754-786. doi: 10.1080/10408347.2020.1772036. Epub 2020 Jun 7. Crit Rev Anal Chem. 2021. PMID: 32506944 Review.
The risk of complications is proportional to the level that blood pressure raises. Calcium channel blockers are a class of compounds used in the treatment of hypertension. The dihydropyridine (DHP) group, a subclass of the calcium channel blo
The risk of complications is proportional to the level that blood pressure raises. Calcium channel blockers are a class …
Vascular smooth muscle cell migration, atherosclerosis, and calcium channel blockers.
Schachter M. Schachter M. Int J Cardiol. 1997 Dec 31;62 Suppl 2:S85-90. doi: 10.1016/s0167-5273(97)00245-3. Int J Cardiol. 1997. PMID: 9488199 Review.
Calcium channel blockers have been studied widely for their potential ability to retard or even reverse atherosclerosis. ...This paper reviews some of the signaling events involved in smooth muscle cell migration, including changes in intracellular calcium
Calcium channel blockers have been studied widely for their potential ability to retard or even reverse atherosclerosis
Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT.
Yamal JM, Oparil S, Davis BR, Alderman MH, Calhoun DA, Cushman WC, Fendley HF, Franklin SS, Habib GB, Pressel SL, Probstfield JL, Sastrasinh S; ALLHAT Collaborative Research Group. Yamal JM, et al. J Am Soc Hypertens. 2014 Nov;8(11):808-19. doi: 10.1016/j.jash.2014.08.003. Epub 2014 Aug 19. J Am Soc Hypertens. 2014. PMID: 25455006 Free PMC article. Clinical Trial.
ALLHAT compared cardiovascular disease outcomes in participants initially treated with an angiotensin-converting enzyme inhibitor (lisinopril), a calcium channel blocker (amlodipine), or a thiazide-type diuretic (chlorthalidone). ...In-tr …
ALLHAT compared cardiovascular disease outcomes in participants initially treated with an angiotensin-converting enzyme inhibitor (lisino
Cholesterol, calcium and atherosclerosis: is there a role for calcium channel blockers in atheroprotection?
Tulenko TN, Laury-Kleintop L, Walter MF, Mason RP. Tulenko TN, et al. Int J Cardiol. 1997 Dec 31;62 Suppl 2:S55-66. doi: 10.1016/s0167-5273(97)00242-8. Int J Cardiol. 1997. PMID: 9488196 Review.
In vitro, the increased calcium permeability is inhibitable by calcium channel blockers (CCBs), but in vivo, a calcium 'leak' pathway develops that is virtually uninhibitable. ...The potential for atheroprotection with amlodipine is curre …
In vitro, the increased calcium permeability is inhibitable by calcium channel blockers (CCBs), but in vivo, a …
66,364 results
You have reached the last available page of results. Please see the User Guide for more information.